Phase I/II Study of the Combination of Inotuzumab Ozogamicin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Latest Information Update: 31 Jan 2025
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Ursodeoxycholic acid (Primary) ; Blinatumomab; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methotrexate; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Dec 2024 Protocol was also amended to increase the number of IT chemotherapy to 12, according to results presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2024 Updated Results (as of July 2024, 75 pts have been treated ) presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Updated Results (As of June 2023, n=75 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition